Citation: | SHI Chen, ZHANG Manlei, ZHOU Xinxin, et al. Correlation study on influenza epidemic in representative 5 cities in the middle and lower reaches of the Yangtze River based on detection of oseltamivir metabolite in wastewater[J]. J China Pharm Univ, 2025, 56(2): 155 − 159. DOI: 10.11665/j.issn.1000-5048.2024062401 |
By selecting stable and detectable drug prototypes or metabolites in sewage samples, near real-time detection of disease conditions can be achieved. This study selected oseltamivir carboxylate, the primary metabolite of first-line antiviral oseltamivir, as a biomarker. Based on the concentration of oseltamivir carboxylate in wastewater, the consumption and usage rate of oseltamivir were calculated by reverse engineering. Quarterly sampling was conducted at 46 urban sewage treatment plants in representative 5 cities in the middle and lower reaches of the Yangtze River, from November 2022 to December 2023. The concentration range of oseltamivir acid in sewage samples is 1.270−1 279 ng/L, the daily mass load of oseltamivir per
[1] |
Hou CZ, Hua ZD, Xu P, et al. Estimating the prevalence of hepatitis B by wastewater-based epidemiology in 19 cities in China[J]. Sci Total Environ, 2020, 740: 139696.
|
[2] |
Pharmaceuticals and Care Products in the Environment[M]. Washington, DC: American Chemical Society, 2001.
|
[3] |
Ahmed F, Tscharke B, O’Brien JW, et al. Wastewater-based prevalence trends of gout in an Australian community over a period of 8 years[J]. Sci Total Environ, 2021, 759: 143460.
|
[4] |
Ahmed F, Tscharke B, O’Brien J, et al. Wastewater-based estimation of the prevalence of gout in Australia[J]. Sci Total Environ, 2020, 715: 136925.
|
[5] |
Shao XT, Zhao YT, Jiang B, et al. Evaluation of three chronic diseases by selected biomarkers in wastewater[J]. ACS EST Water, 2023, 3(4): 943-953.
|
[6] |
Liu SC, Zhou XX, Zhang ML, et al. Estimating the prevalence of dyslipidemia by measuring fenofibrate in 33 cities in China[J]. Sci Total Environ, 2024, 912: 169426.
|
[7] |
Shao XT, Wang YS, Gong ZF, et al. Surveillance of COVID-19 and influenza a (H1N1) prevalence in China via medicine-based wastewater biomarkers[J]. Water Res, 2023, 247: 120783.
|
[8] |
Lu HJ, Fan JP, Guo CS, et al. Estimating the prevalence of depression using wastewater-based epidemiology: a case study in Qinghai Province, West China[J]. Sci Total Environ, 2023, 882: 163303.
|
[9] |
General office of National Health Commission, National Administration of Traditional Chinese Medicine. Guidelines for diagnosis and treatment of influenza(2020 version)[J]. Chin J Viral Disease(中国病毒病杂志), 2021, 11(1): 1-5.
|
[10] |
Pan XY, Ling F. Research progress on adverse reactions of oseltamivir[J]. China Med(中国医药)2023, 18 (09): 1423-1427.
|
[11] |
Tang T, Rao HL, Li LT, et al. Analysis of the use of anti-influenza virus drugs in Nanjing area from 2017 to 2019[J]. Drugs Clinic(现代药物与临床), 2021, 36(5): 1045-1050.
|
[12] |
Abe M, Smith J, Urae A, et al. Pharmacokinetics of oseltamivir in young and very elderly subjects[J]. Ann Pharmacother, 2006, 40(10): 1724-1730.
|
[13] |
Leknes H, Sturtzel IE, Dye C. Environmental release of oseltamivir from a Norwegian sewage treatment plant during the 2009 influenza A (H1N1) pandemic[J]. Sci Total Environ, 2012, 414: 632-638.
|
[14] |
Ghosh GC, Nakada N, Yamashita N, et al. Occurrence and fate of oseltamivir carboxylate (Tamiflu) and amantadine in sewage treatment plants[J]. Chemosphere, 2010, 81(1): 13-17.
|
[15] |
Singer AC, Järhult JD, Grabic R, et al. Intra- and inter-pandemic variations of antiviral, antibiotics and decongestants in wastewater treatment plants and receiving rivers[J]. PLoS One, 2014, 9(9): e108621.
|
[16] |
Chinese Center for Disease Control and Prevention. Epidemic situation of novel coronavirus infection in China[EB/OL]. (2024-01-10)[2024-01-11]. https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202401/t20240110_271902.html.
|
[17] |
Li HB, Yang HG. How is the trend of influenza developing? Central Disease Control and Prevention: some provinces have seen turning points. (2023-03-21)[2024-01-11]. http://kpzg.people.com.cn/n1/2023/0321/c404214-32647867.html.
|
[18] |
China National Influenza Center. 19th week 2023, 752nd issue of China’s influenza monitoring weekly report[EB/OL]. (2023-05-17)[2024-01-11]. https://ivdc.chinacdc.cn/cnic/zyzx/lgzb/202305/t20230518_266049.htm.
|
[19] |
China National Influenza Center. 24th week 2023, 757th issue of China’s influenza monitoring weekly report[EB/OL]. (2023-06-21)[2024-01-11]. https://ivdc.chinacdc.cn/cnic/zyzx/lgzb/202306/t20230622_267062.htm.
|
[20] |
China National Influenza Center. 46th Week 2023, 779th issue of China’s influenza monitoring weekly report[EB/OL]. (2023-11-23)[2024-01-11]. https://ivdc.chinacdc.cn/cnic/zyzx/lgzb/202311/t20231123_270811.htm.
|
[21] |
China National Influenza Center. 50th week, 2023, 783rd issue of China’s influenza monitoring weekly report[EB/OL]. (2023-12-21)[2024-01-11]. https://ivdc.chinacdc.cn/cnic/zyzx/lgzb/202312/t20231222_271493.htm.
|
[1] | LIU Shengfeng, ZHANG Lan, LIU Shucheng, HOU Chenzhi, XU Peng, DI Bin. Phase I metabolism of four amide synthetic cannabinoids in human liver microsomes[J]. Journal of China Pharmaceutical University, 2022, 53(5): 577-590. DOI: 10.11665/j.issn.1000-5048.20220508 |
[2] | LIANG Yixuan, WU Jie. Expression, purification and NETs degradation activity of human DNase I[J]. Journal of China Pharmaceutical University, 2019, 50(1): 93-99. DOI: 10.11665/j.issn.1000-5048.20190113 |
[3] | YAO Jian, SHAO Lei, CHEN Daijie, ZHANG Yubin. Transcriptomic analysis of a spiramycin I-resistant Staphylococcus aureus mutant[J]. Journal of China Pharmaceutical University, 2017, 48(6): 738-744. DOI: 10.11665/j.issn.1000-5048.20170617 |
[4] | XU Yinrong, SHENG Xiaoxia. A reliable crystallization process for the preparation of agomelatine form I[J]. Journal of China Pharmaceutical University, 2016, 47(2): 171-175. DOI: 10.11665/j.issn.1000-5048.20160208 |
[5] | Kong Lingyi, Li Yi, Min Zhida. Study on Analysis of Pd Ia in Peucedanum Praerupto rum and Pd C I in Peucedanum Decursivum by RP HPLC[J]. Journal of China Pharmaceutical University, 1996, (4). |
[6] | Asymmetric Cyclization Using Rhodium(I)with Chiral Ligand[J]. Journal of China Pharmaceutical University, 1995, (6): 324-328. |
[7] | Pharmacognostical Studies on the Chinese Drug Fupenzi I[J]. Journal of China Pharmaceutical University, 1994, (4): 4-9. |
[9] | PHYTOCHEMICAL STUDY OF LYSIMACHIA FOENUMGRAECUM I[J]. Journal of China Pharmaceutical University, 1989, (1): 37-39. |
[10] | COMPARATIVE STUDIES ON THE ANTIARRHYTHEMIC EFFECTS OF GUANFU BASE G WITH GUANFU BASE A AND I[J]. Journal of China Pharmaceutical University, 1987, (4): 268-272. |